Background

Canada enacted a two-fold reform of its drug patent regime in 1987 (Bill C-22) that sought to balance competing industrial and social policy objectives:

- Strengthen patent protection for drug manufacturers to incentivize R&D
- Mitigate the financial impact of stronger pharmaceutical patent protection on payers

The PMPRB was conceived as C-22’s “consumer protection pillar”, to ensure patentees do not abuse their newfound statutory monopolies by charging excessive prices.

The intent was to double R&D in Canada (to 10% of revenues) while keeping prices in line with high R&D countries (the PMPRB-7)* on the assumption we would come to emulate them.

*Countries in the PMPRB-7 are Italy, France, Germany, Sweden, Switzerland, the UK and the US.
The PMPRB is part of a complex regulatory and reimbursement ecosystem.

Drug Life Cycle
- R&D
- Patented
- Generic

Health Canada
- Review for Safety, Efficacy and Quality
- Post market surveillance

PMPRB
- Excessive Price Monitoring and Investigation

Private Drug Plans
- Reimburse

CADTH
- CDR / pCODR

Provinces
- pCPA
- Reimburse

CADTH: Canadian Agency for Drugs and Technologies in Health
pCPA: Pan-Canadian Pharmaceutical Alliance
The PMPRB’s authority to regulate patented drug prices reposes on three legal instruments:

- **Sections 79-103 of the Patent Act**: excessivity factors, mandate, jurisdiction, structure and powers of the Board;

- **Patented Medicines Regulations**: comparator countries, information required of patentees on identity, prices of medicines and R&D investment;

- **Compendium of Policies, Guidelines and Procedures (“Guidelines”)**: scientific and price review process, price tests for new and existing drugs.
<table>
<thead>
<tr>
<th>Breakthrough</th>
<th>Substantial Improvement</th>
<th>Moderate Improvement</th>
<th>Slight/no Improvement</th>
<th>New Presentation of an Existing Drug</th>
</tr>
</thead>
</table>
| No comparator | Drug products over which drug under review brings substantial improvement | Drug products over which drug under review brings moderate improvement | Drug products over which drug under review brings slight/no improvement | Same active ingredient  
Same indication /use  
Same or comparable dosage form |
| MIPC         | Higher of  
- Top of TCC  
- MIPC  
(Average of top of TCC and MIPC)  
-Top of TCC | Higher of:  
- Mid point  
Top of TCC  
Comparable drug products:  
Top of TCC | No comparators; only “superior”  
Lower of:  
- Bottom of TCC | RR test if same dosage regimen  
TCC if different dosage regimen |

If cannot derive dosage regimen or price of comparator(s) is excessive: MIPC test

Highest International Price Comparison (HIPC) test
Problems with current approach

Our basket of comparators includes the US, an international outlier.

Our system focuses on rewarding therapeutic benefit instead of policing the risk of abuse/excessive pricing.

Our only absolute ceiling for existing drugs is highest international price.

Me-too drugs can be priced at the top of the domestic therapeutic class.

It is based on publicly available list prices, which are increasingly divorced from the true price net of confidential rebates/discounts.

It is not working: prices are high and R&D is low.
Canada, like many countries, faces rising health care costs as payers struggle to reconcile finite budgets with patient access to promising new health technologies.

In addition to relatively high utilization, Canada pays among the highest prices in the world for patented and generic drugs.

A surge in high cost drugs is driving public drug plan spending back into double digit growth and is accounting for a disproportionate share of total pharmaceutical spending in Canada.

Making prescription drugs more affordable is a shared FPT priority.

Framework modernization is one of the PMPRB’s 2015-2018 strategic priorities.

As a first step, PMPRB is currently consulting on Guideline reform.
In addition to relatively high pharmaceutical utilization, Canada pays among the highest prices in the world for both patented and generic drugs.

Foreign-to-Canada price ratios

Patented (OECD, 2015)

Parameter | Value
--- | ---
USA | 2.57
Mexico | 1.07
Canada | 1.00
Germany | 0.99
Japan | 0.91
New Zealand | 0.89
Sweden | 0.89
Austria | 0.88
Chile | 0.86
Ireland | 0.82
UK | 0.82
Finland | 0.81
Italy | 0.79
Australia | 0.78
Belgium | 0.78
Spain | 0.78
France | 0.77
Median | 0.75
Hungary | 0.75
Netherlands | 0.74
Luxembourg | 0.73
Norway | 0.73
Slovakia | 0.72
Poland | 0.72
Portugal | 0.69
Greece | 0.66
Estonia | 0.64
Czech Republic | 0.62
South Korea | 0.50
Turkey | 0.38

Generic (PMPRB7, Q4-2015)

Parameter | Value
--- | ---
USA | 1.67
Canada | 1.11
France | 0.87
UK | 0.86
Germany | 0.76
Italy | 0.75
Sweden | 0.53
Median | 0.73

Sources: PMPRB Annual Report 2015; National Prescription Drug Utilization Information System Database
High cost drugs

Total public spending on high cost drugs doubled in 2015.

Public plan drug cost annual change by market segment

- All drugs: 12.2%
- Patented: 19.1%
- Multi-source generic: 2.5%
- Non-patented single-source: 33.2%
- High cost drugs > $10,000: 104.9%
- Biologics: 9.8%
- Other patented drugs: 24.6%

Expenditure share by market segment

- Patented: 56.6%
- Multi-source generic: 24.5%
- Non-patented single-source: 16.5%
- Other: 2.4%

Source: National Prescription Drug Utilization Information System Database
High cost drugs

Growth in public drug plan spending has returned to double digits.

Public Drug Plan Spending

- Use of more drugs by more patients
- Use of more expensive drugs (drug-mix)
- Savings from generic drug use and pricing

Source: National Prescription Drug Utilization Information System Database
"A Liberal government’s... priorities for a new Health Accord will include:

We will consult with industry and review the rules used by the Patented Medicine Prices Review Board to ensure value for the money governments and individual Canadians spend on brand name drugs."

Guidelines reform
Consultation on Guidelines reform

In June, the PMPRB commenced consultations by issuing a discussion paper on Guidelines reform.

The paper encourages stakeholders and the public to take a fresh look at how the PMPRB interprets and applies the Act and Regulations in light of recent changes in its operating environment.

It also highlights aspects of the Guidelines that are thought to be particularly outdated, including:

1. How therapeutic benefit is applied
2. How therapeutic class is defined and applied
3. International and domestic price tests
4. How CPI is applied
5. “Any market” price review/price discrimination

Feedback received to the questions in the paper will inform the second phase of consultations, when specific changes to the Guidelines will be proposed.
To the extent there is common ground (relatively) among a disparate group of stakeholders, it is mainly with respect to the following points:

- The PMPRB is relevant and has a distinct role to play by protecting consumers from excessive prices;
- The PMPRB should complement and not duplicate the role played by other participants in the Canadian pharmaceutical system (e.g., CADTH, pCPA);
- The PMPRB should prioritize drugs based on risk factors of abuse;
- The PMPRB should adopt “bright line” rules that are informed by international best practices and provide predictability and certainty to stakeholders;
- “Value” is an important consideration in assessing whether a price is excessive
  - Continued belief in the idea that patents and value-based-pricing encourage the “right” kind of innovation
- Legislative and/or regulatory change should precede Guideline reform.
Public feedback on Guideline reform

To the extent there is disagreement (relatively), it is mainly with respect to the following points:

- Whether “affordability” and excessivity are related concepts;
- What countries Canada should compare itself to and how ceilings should be set;
- What risk factors should be considered in prioritizing drugs;
- Whether, how and when to “rebench”
- Whether price disparities between different types of payers can be considered excessive;
- Temporal application of revised Guidelines
Canada and the developed world is signaling a need to find solutions to ever increasing drug budget pressures.

The “patent cliff” savings from the era of mass-marketed, so-called “blockbuster” medicines are not expected to continue to finance innovation.

The drug pipeline is increasingly moving towards specialty drugs that target less common, untreated, and severe illnesses but at a price even the most well-funded payers struggle to afford.

Growing concern over sustainability has led other countries to introduce measures to address affordability, maximize value for money and keep pace with a rapidly evolving market.

PMPRB reform needs learn from international best practices and adapt regulation to the Canadian drug approval, economic assessment and reimbursement landscape context.

All stakeholders, including industry, stand to win from a price regulator that contributes to the long term sustainability of Canada’s health care system.
# Next steps

<table>
<thead>
<tr>
<th>Phase</th>
<th>Steps</th>
<th>Timelines</th>
</tr>
</thead>
</table>
| Phase 1: Consult on Discussion Paper | • Publish Discussion Paper and meet with stakeholders  
• Obtain written comments on the Discussion Paper  
• Gather and analyze all results from Phase 1 of consultation | Summer/Fall 2016 |
| Phase 2: Public policy hearing | • Invite stakeholders to appear before the Board and make representations in support of their written submissions | Winter/Spring 2017 |
| Phase 3: Consult on draft revised Guidelines | • Publish proposed changes to Guidelines for public comment  
• Strike multi-stakeholder forum(s) on specific issues and explore options for specific changes to the Guidelines | Fall 2017 |